Veterinary Autoimmune Disease Therapeutics Market – By Therapy (Corticosteroids, Azathioprine), Disease (Hypothyroidism, Pemphigus Disease), Animal Type (Companion, Livestock), Distribution Channel (Hospitals, Clinics), Global Forecast (2023 - 2032)

Veterinary Auto-immune Therapeutics Market Size

Veterinary Auto-immune Therapeutics Market size was valued to be USD 3.1 billion in 2022 and is expected to reach USD 5.2 billion in 2032 with a CAGR of 5.3% from 2023 to 2032 owing to increasing threat of transfer of zoonotic diseases among human, rising incidence of auto-immune diseases in livestock animals, increasing awareness and diagnosis of autoimmune diseases, growing companion animal ownership, increasing expenditure on animal healthcare, and increasing in animal health medicalization rate.
 

The veterinary auto-immune therapeutics are drugs which are used when the immune system does not work properly in animals and starts to attack the own tissues or organs. Some examples of auto-immune diseases in animals are pemphigus vulgaris, autoimmune haemolytic anemia, canine systemic lupus, rheumatoid arthritis etc. These diseases can occur with no identifiable cause or can result from infections, cancer, or specific drugs. The focus of auto-immune therapeutics is to control the immunological response. They are used to decrease or reduce the symptoms and inflammation, decrease the associated pain, or inhibit the inappropriate immune response.
 

COVID-19 Impact

Many veterinary hospitals and clinics experienced temporary closures or restrictions during the pandemic as a result of lockdowns, social distancing laws, and the prioritization of essential services. Only serious veterinary cases were permitted to enter veterinary hospitals during such times. Hence, Covid-19 has a significant influence on the entire veterinary pharmaceuticals market including auto-immune disease therapeutics.
 

Travel and commuting issues hampered market expansion, which ultimately resulted in a decline in the demand for veterinary auto-immune treatments. Moreover, the pandemic caused disruption in the supply chain, including in the animal health industry. Supply and demand were severely impacted by the loss of labour and human resources, which restrained expansion.
 

On the other hand, the COVID-19 pandemic resulted in a significant rise in pet ownership. During lockdowns, a large population sought companionship, leading to a surge in pet adoption. This increase in pet ownership has positively impacted the overall animal healthcare market.  The increasing prevalence of veterinary auto-immune diseases leads to the increase in the demand for faster and efficient therapeutic and treatment options.
 

Veterinary Auto-immune Therapeutics Market Trends

Some key trends in the market includes growing awareness among pet owners and veterinarians regarding autoimmune diseases in animals, and rising demand for auto-immune therapeutics among companion animals due to the high risk of HIV transmission from an animal source to human with weakened immunity and the transmission of allergy components from companion animals to family members.
 

The increasing pet ownership is also a key factor driving the growth of market.  According to the American Pet Products Association's (APPA) 2021-2022 National Pet Owners Survey, 70% of the U.S. households, or around 90.5 million families, own a pet and this number is expected to increase in future Increasing companion animal ownership leads to rise on animal healthcare, in turn to an increase in the medicalization rate for animals.
 

Veterinary Auto-immune Therapeutics Market Analysis

Based on the type of therapy, the veterinary auto-immune therapeutics market is segmented into corticosteroids, azathioprine, cyclosporine, mycophenolate, leflunomide, cyclophosphamide, levothyroxine, folic acid, hydroxychloroquine, and chloroquine. Corticosteroids held the highest revenue of USD 1.1 billion in 2022 and expected to grow in the forecast period. Corticosteroids are potent anti-inflammatory agents. In veterinary medicine, many autoimmune conditions involve an excessive immune response and inflammation, leading to tissue damage. Corticosteroids help mitigate inflammation by suppressing the immune system's response, reducing the severity of symptoms, and providing relief to affected animals.
 

Based on diseases, the veterinary auto-immune therapeutics market is divided into hypothyroidism, pemphigus disease, canine lupus, auto-immune haemolytic anaemia, bullous pemphigoid, discoid lupus erythematosus, immune-related arthritis, and other diseases. In 2022, the hypothyroidism segment accounted for the largest share of 30.7% in the market. Hypothyroidism is most common in dogs but also develops rarely in other animals like cats, horses, and other companion animals.
 

Based on animal type, the veterinary auto-immune therapeutics market is subdivided into companion animals, livestock animals, and other animals. The companion animal segment is further subdivided into dogs, cats, horses, and other companion animals. The livestock animal segment is further subdivided into cattle, swine, poultry, sheep, and other livestock animals. The companion animal segment held the largest market share of 61.3% in 2022. The key factors supporting the growth of this segment are the rapidly increasing pet ownership, the high prevalence of zoonotic diseases, the increasing adoption of pet insurance, and the increasing need of diagnostics and adequate treatment.
 

Based on distribution channel, the veterinary auto-immune therapeutics market is classified into veterinary hospitals and veterinary clinics. Veterinary hospitals held the largest share of 57.7% in 2022 owing to the well-established facilities for treatment and availability of wide range of medications in hospitals. The increasing prevalence of zoonotic diseases, the growing need of diagnostics, the increasing visits to veterinary hospitals and clinics, and the increasing number of veterinary practitioners are the factors driving the market trends.
 

North America veterinary auto-immune therapeutics market accounted for significant revenue in 2022 and is expected to reach USD 2.2 billion in 2032 with a CAGR of 5.5% from 2023-2032. North America has a large population of companion animals, including dogs, cats, and horses. The bond between pet owners and pets is getting strong and pet owners are focusing on pet’s health. As more people consider their pets as family members, the demand for advanced veterinary care rises. Pet owners are increasingly seeking effective treatments for their animals’ autoimmune disorders, driving the demand for relevant therapeutics in the region
 

Veterinary Auto-immune Therapeutics Market Share

The prominent players in the veterinary auto-immune therapeutics market are :

• Aratana Therapeutics inc.
• Pfizer Inc.
• Vet-Stem Inc.
• Ambrx Inc.
• Taconic Biosciences Inc.
• JBS United
• Virbac
• Eli Lily and Company
• Jaguar Animal Health Inc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
 

The global Veterinary Auto-immune Therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market Size, By Therapy Type

• Corticosteroids
• Azathioprine
• Cyclosporine
• Mycophenolate
• Leflunomide
• Cyclophosphamide
• Levothyroxine
• Folic acid
• Hydroxychloroquine
• Chloroquine

Market Size, By Disease

• Hypothyroidism
• Pemphigus disease
• Canine lupus
• Auto-immune haemolytic anaemia
• Bullous pemphigoid
• Discoid lupus erythematosus (DLE)
• Immune-related arthritis
• Other diseases

Market Size, By Animal Type

• Companion animals
  • Dogs
  • Cats
  • Horses
  • Other companion animals
• Livestock animals
  • Cattle
  • Swine
  • Poultry
  • Sheep
  • Other livestock animals
• Other animals

Market Size, By Distribution Channel

• Veterinary hospitals
• Veterinary clinics

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa